Company intelligence / Profile preview

Cardionomic

New Brighton, Minnesota, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~21
Development stage: Phase 2

Overview

Initial pilot studies for the CPNS System demonstrated promising efficacy in treating acute decompensated heart failure by electrically stimulating autonomic cardiac nerves via a temporary catheter in the pulmonary artery. The target population was hospitalized ADHF patients with reduced ejection fraction and fluid overload despite diuretics. Clinical results showed significant positive outcomes, but further trials are needed to confirm efficacy and safety before commercialization.

Therapeutic areas: Cardiovascular
Modalities: DeviceNeuromodulation therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

CPNS System

Phase 2

Indications: Acute decompensated heart failure

Partnerships

Cleveland Clinic FoundationAbbott LaboratoriesNew Enterprise Associates (NEA)

Beyond the preview

Go deeper on Cardionomic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardionomic.

Explore the full profile